Actively Recruiting
hepatomiR cACLD Study
Led by Karl Landsteiner University of Health Sciences · Updated on 2025-09-09
156
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
Sponsors
K
Karl Landsteiner University of Health Sciences
Lead Sponsor
U
University Hospital St. Polten
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.
CONDITIONS
Official Title
hepatomiR cACLD Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with chronic liver disease lasting more than 6 months
- Liver stiffness measurement of 10 kPa or higher
- Receiving outpatient care at the Clinical Department of Internal Medicine II, University Hospital St. P�f6lten
- Signed patient consent form
You will not qualify if you...
- Younger than 18 years old
- Pregnant
- Diagnosis of primary hepatic cancer (hepatocellular carcinoma or cholangiocarcinoma) with portal invasion or spread beyond the liver
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital St. Pölten
Sankt Pölten, Lower Austria, Austria, 3100
Actively Recruiting
Research Team
L
Lukas Erhart, Mag. Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here